StockNews.com began coverage on shares of Oragenics (NYSE:OGEN – Free Report) in a research note released on Wednesday morning. The firm issued a sell rating on the stock.
Oragenics Price Performance
OGEN stock opened at $1.10 on Wednesday. The business has a 50-day moving average of $1.83. Oragenics has a 12 month low of $1.02 and a 12 month high of $7.74. The company has a market capitalization of $4.93 million, a PE ratio of -0.12 and a beta of 0.31.
Oragenics (NYSE:OGEN – Get Free Report) last announced its quarterly earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Further Reading
- Five stocks we like better than Oragenics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- High-Yield Texas Instruments Could Hit New Highs Soon
- Investing In Preferred Stock vs. Common Stock
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Best Fintech Stocks for a Portfolio Boost
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
